Gloved healthcare worker drawing medication from a vial into a syringe

Committed to Clearly Differentiated
CAR-T Therapies

At T-CURX, we develop next-generation CAR-T therapies with the ambition to deliver durable responses, enhance safety, and make innovative cancer treatments accessible to more patients.

Our clinical-stage lead program, targeting Siglec-6, is designed to address a critical unmet need in Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL) by selectively eliminating malignant cells while sparing healthy hematopoietic stem cells. This may eliminate the need for subsequent stem cell transplantation.

Leveraging our clinical experience with ex vivo CAR-T programs, validated target biology, and proprietary non-viral CAR and LNP technologies, we are transitioning toward in vivo CAR-T therapies. Our ambition is to generate CAR-T cells directly within patients via proprietary mRNA and minicircle DNA (mcDNA) payloads and targeted delivery via our LNP technology.

We are advancing a differentiated non-viral in vivo CAR-T pipeline with the potential to deliver durable therapeutic responses, starting with hard-to-treat hematological malignancies such as AML, with subsequent expansion into solid tumor indications.

Our Pipeline

Discovery Pre-clinical CTA Phase 1 Phase 2a Indication Antigen Sponsor AML & CLL Siglec-6 BCL & Solid tumors Not disclosed Not disclosed Not disclosed Hematology Not disclosed Solid tumors Not disclosed AML acute myeloid leukemia · CLL chronic lymphocytic leukemia · BCL B-cell lymphoma · CTA clinical trial application TCX-001 Academic Partner ex vivo in vivo
AML & CLL
Siglec-6 · TCX-001
Disc.Pre-cl.CTAPh 1Ph 2a
BCL & Solid tumors Academic Partner
Not disclosed
Disc.Pre-cl.CTAPh 1Ph 2a
Not disclosed
Not disclosed
Disc.Pre-cl.CTAPh 1Ph 2a
Hematology
Not disclosed
Disc.Pre-cl.CTAPh 1Ph 2a
Solid tumors
Not disclosed
Disc.Pre-cl.CTAPh 1Ph 2a

Clinical Studies